GlaxoSmithKline Pharmaceuticals Limitec
GSK House, Dr. Annie Besant Road
Worli, Mumbai - 400 03C
Tel No: +91 22 2495 959!
Fax No: +91 22 2495 949
Web: www.gsk-india.com
Email: askus@gsk.com

1st August 2025

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Outcome of Board Meeting

Pursuant to Regulation 33 read with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, the Board of Directors of the Company at its meeting held today considered and approved the Un-audited Standalone and Consolidated Financial Results for the first quarter ended 30th June 2025. Please find enclosed herewith the Un-audited Standalone and Consolidated Financial Results for the first quarter ended 30th June 2025 and Limited Review Report of the Auditors thereon.

The Meeting of the Board of Directors of the Company commenced at 10.30 a.m. and concluded at 12.30 p.m.

This is for your information and record.

Thanking you,

Yours faithfully,
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President - Administration, Real Estate
& Company Secretary

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2025	Preceeding 3 months ended 31.03.2025	Corresponding 3 months ended 30.06.2024	Year ended 31.03.2025
		(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited)
	Income				
1	Revenue from operations	80483	96608	81100	372349
2	Other income	4376	3946	3585	14256
3	**Total Income (1+2)**	**84859**	**100554**	**84685**	**386605**
	Expenses				
	(a) Cost of materials consumed	12143	10835	13333	47086
	(b) Purchases of stock-in-trade	23207	29140	17274	84511
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(6553)	(5341)	(1326)	5123
	(d) Employee benefits expense	15257	15297	15128	57970
	(e) Finance costs	42	58	37	131
	(f) Depreciation and amortisation expense	1552	1472	1641	6679
	(g) Other expenses	11354	13603	13749	60730
4	**Total expenses**	**57002**	**65064**	**59836**	**262230**
5	**Profit before exceptional items and tax (3-4)**	**27857**	**35490**	**24849**	**124375**
6	Exceptional items (credit) (Refer Note 4)	-	-	-	469
7	**Profit before tax (5+6)**	**27857**	**35490**	**24849**	**124844**
8	Tax expense				
	(a) Current tax	7385	8934	6333	32318
	(b) Deferred tax	2	542	351	620
9	**Profit for the period/year (7-8)**	**20470**	**26014**	**18165**	**91906**

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2025	Preceeding 3 months ended 31.03.2025	Corresponding 3 months ended 30.06.2024	Year ended 31.03.2025
		(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited)
10	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss	-	(512)	-	(355)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	128	-	89
11	**Total comprehensive income for the period (9+10)**	**20470**	**25630**	**18165**	**91640**
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941
	Other equity				177982
	Earnings per share (EPS) (of Rs. 10 each)				
	Basic and diluted EPS before Exceptional items (Rs.)	12.08	15.35	10.72	54.01
	Basic and diluted EPS after Exceptional items (Rs.)	12.08	15.35	10.72	54.24
		Not Annualised			

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 01st August 2025. The Statutory auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June 2025.
2. The figures for the 3 months ended 31st March 2025 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March 2025.
3. Final dividend of Rs. 42 per equity share for the year ended 31st March 2025 had been approved by the shareholders in the Annual General meeting held on 27th June 2025.
4. Exceptional items credit for the year ended 31st March 2025 of Rs.469 lakhs is on account of profit on sale of surplus residential properties
5. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

By Order of the Board

Bhushan Akshikar
Managing Director
DIN: 09112346

01st August, 2025

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs. in Lakhs)

Particulars	3 months ended 30.06.2025	Preceding 3 months ended 31.03.2025	Corresponding 3 months ended 30.06.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited)
Income				
Revenue from operations	80517	97437	81465	374921
Other income	4372	4068	3564	14593
Total Income (1+2)	**84889**	**101505**	**85029**	**389514**
Expenses				
(a) Cost of materials consumed	12806	11523	13823	49990
(b) Purchases of stock-in-trade	23206	29140	17274	84511
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(7241)	(5469)	(1570)	4585
(d) Employee benefits expense	15257	15297	15128	57970
(e) Finance costs	42	58	37	131
(f) Depreciation and amortisation expense	1552	1472	1641	6679
(g) Other expenses	11369	13627	13756	60129
Total expenses	**56991**	**65648**	**60089**	**263995**
Profit before exceptional items and tax (3-4)	**27898**	**35857**	**24940**	**125519**
Exceptional items (credit) (Refer Note 4)	-	-	-	469
Profit before tax (5+6)	**27898**	**35857**	**24940**	**125988**
Tax expense				
(a) Current tax	7395	9015	6356	32596
(b) Deferred tax	2	555	351	634
Profit for the period/year (7-8)	**20501**	**26287**	**18233**	**92758**

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2025	Preceding 3 months ended 31.03.2025	Corresponding 3 months ended 30.06.2024	Year ended 31.03.2025
		(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited)
0	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss	-	(512)	-	(355)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	128	-	89
1	**Total comprehensive income for the period (9+10)**	**20501**	**25903**	**18233**	**92492**
2	**Total comprehensive income for the period attributable to owners of the Group**	**20501**	**25903**	**18233**	**92492**
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941
	Other equity				178190
	Earnings per share (EPS) (of Rs. 10 each)				
	Basic and diluted EPS before Exceptional items (Rs.)	12.10	15.52	10.76	54.52
	Basic and diluted EPS after Exceptional items (Rs.)	12.10	15.52	10.76	54.76
		Not Annualised			

Notes:

. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 01st August 2025. The Statutory auditors have carried out a limited review of the consolidated financial results for the quarter ended 30th June 2025.

. The figures for the 3 months ended 31st March 2025 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March 2025.

. Final dividend of Rs. 42 per equity share for the year ended 31st March 2025 had been approved by the shareholders in the Annual General meeting held on 27th June 2025.

. Exceptional items credit for the year ended 31st March 2025 of Rs.469 lakhs is on account of profit on sale of surplus residential properties.

. The Group has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

By Order of the Board

Bhushan Akshikar
Managing Director
DIN: 09112346

01st August, 2025

Deloitte Haskins & Sells LLP

Chartered Accountants
One International Center,
Tower 3, 31st Floor,
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai - 400 013
Maharashtra, India

Tel: +91 22 6185 4000
Fax: +91 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of GlaxoSmithKline Pharmaceuticals Limited ("the Company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Rupen K. Bhatt
Partner
(Membership No. 046930)
UDIN: 25046930BMODSJ4825

Place: Mumbai
Date: August 1, 2025

Deloitte Haskins & Sells LLP

Chartered Accountants
One International Center,
Tower 3, 31st Floor,
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai - 400 013
Maharashtra, India

Tel: +91 22 6185 4000
Fax: +91 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF GLAXOSMITHKLINE PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of GlaxoSmithKline Pharmaceuticals Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the Parent and its subsidiary – Biddle Sawyer Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Deloitte
Haskins & Sells LLP

6. We did not review the interim financial results of the subsidiary included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 282 lakhs for the quarter ended June 30, 2025, total net profit after tax of Rs. 30 lakhs for the quarter ended June 30, 2025 and total comprehensive income of Rs. 30 lakhs for the quarter ended June 30, 2025, as considered in the Statement. These interim financial results have been reviewed by the other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Rupen K. Bhatt
Partner
(Membership No. 046930)
UDIN: 25046930BMODSK8220

Place: Mumbai
Date: August 01, 2025